Efficacy and Tolerability of Ambroxol Lozenge 20 mf in Relieving Pain of Sore Throat in Pat. With Acute/Viralpharyngitis

Pharyngitis Clinical Trial

Official title:

Efficacy and Tolerability of Ambroxol Lozenge 20 mg in Relieving Pain of Sore Throat in Patients With Acute Viral Pharyngitis-A Randomised, Double-blind,Placebo- and Active-controlled Parallel Group Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00148499
• Other study ID #: 18.489
• Status: Completed
• Phase: Phase 3
• First received: September 7, 2005
• Last updated: December 27, 2017
• Start date: October 2005
• Est. completion date: June 2006

Study information

• Verified date: December 2017
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is to investigate efficacy and tolerability of lozenges containing 20 mg a mbroxol hydrochloride (Mucoangin?) relative to lozenges containing placebo and lozenges containing 3 mg benzocaine in relieving pain of sore throat in patients suffering from acute viral pharyngitis.

Description:

This is a randomised, double-blind, placebo- and active-controlled parallel group study in adult pat ients, suffering from acute viral pharyngitis and throat pain of at least moderate intensity.

The whole study will last for up to 4 days, on each of test days patients will take one lozenge cont aining Ambroxol hydrochlorid 20 mg/ or placebo/ or benzocaine lozenge 3 mg up to 6 lozenges per day.

Using Patient Diaries the assessment of tolerability and efficacy by the patient will be obtained.

Study Hypothesis:

The primary hypothesis to be tested is the test of superiority of ambroxol 20 mg in comparison to placebo. If and only if the corresponding test of superiority to placebo is statistically significant, the hypothesis of non-inferiority of am broxol 20 mg in comparison to benzocaine 3 mg will be tested.

Comparison(s):

For the primary comparison the placebo lozenges will be used, for the secondary comparison the benzocaine 3 mg lozenges will be used.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 751
• Est. completion date: June 2006
• Est. primary completion date: June 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

INCLUSION CRITERIA

1. Patients having a sore throat with acute viral pharyngitis.

2. Female and male patients between the ages of 18 and 80 years.

3. The throat pain intensity is rated at least moderate on the VRS (PI).

4. Written Informed Consent is given by the patient.

5. Compliance by the patient seems guaranteed, and patient seems to be able to understand and complete the patient diary.

6. Patient able to remain at the doctor's practice for the initial 3 hours follo wing the first intake of study medication, and able to return for the study visi ts.

EXCLUSION CRITERIA

1. Female patients of child-bearing potential that are:

1. Pregnant

2. Currently breastfeeding

3. NOT practicing acceptable methods of birth control, or NOT planning to contin ue practicing an acceptable method throughout the study. Acceptable methods of birth control include surgical sterilisation, intra uterine device, oral, implan table, injectable contraceptives or double-barrier method.

2. Patients with symptoms of primarily bacterial pharyngitis or bacterial secon dary infection (clinical findings inter alia assessment of exudate).

3. First indication of symptoms of acute pharyngitis (e.g. sore throat) occurre d more than 3 days ago.

4. Patients who suffered from acute viral or bacterial pharyngitis in the past 4 weeks.

5. Patient who in the past week, or during the study will require treatment with the following: antibiotics steroids for oral, inhaling or topical application expectorants or antitussives. No physical therapy (e.g. throat compress, throa t rinsing) may be applied during the trial. Patients who have used analgesics or anti-inflammatory agents less than two half-lives of the applicable drug before study entry, or who will require their use in the 3 hours after taking the firs t lozenge.

6. Patients with mouth breathing as a result of nasal congestion.

7. Known hypersensitivity to Ambroxol or to auxiliary substances contained in t he lozenge.

8. Existing tumour condition currently under treatment.

9. Alcohol, and/or drug abuse.

10. Any clinical condition which, in the opinion of the investigator would not a llow safe completion of the protocol and safe administration of trial medication.

11. Any investigational therapy within 30 days prior to randomisation.

Related Conditions & MeSH terms

• Pharyngitis

Intervention

Drug:
• Ambroxol hydrochloride (Mucoangin?)

• benzocaine

Locations

Country	Name	City	State
Romania	Medicover	Bucharest
Romania	Medicover	Bucharest
Romania	Medicover	Bucharest
Romania	Victor Babes Clincial Hospital	Bucharest
Ukraine	City Clinical Hospital No. 11	Kharkov
Ukraine	City Clinical Hospital No. 17	Kharkov
Ukraine	City Clinical Hospital No. 26	Kharkov
Ukraine	City Clinical Otolaryngological Hospital	Kharkov
Ukraine	Regional Clinical Hospital	Kharkov
Ukraine	Regional Student Hospital	Kharkov
Ukraine	Academy of Medical Science named after O.S. Kolomyichenko	Kiev
Ukraine	City Clinical Hospital No. 9	Kiev
Ukraine	City Clinical Hospital No. 11	Odessa
Ukraine	Regional Clinical Hospital	Zaporozhye

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

Romania,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Endpoint: Time-weighted average of the pain intensity difference from pre-dose baseline over the first 3 hours after the first lozenge expressed as a ratio of the pre-dose baseline (SPIDnorm)
Secondary	Pain intensity (PI) and pain intensity difference from pre-dose baseline (PID) Time to onset of action after the first lozenge Assessment of efficacy Assessment of tolerability by the patient and investigator Adverse events

External Links

•   Link